Novonesis (Novozymes) stock (DK0060336014): enzyme merger creates new earnings story

After the merger of Novozymes and Chr. Hansen into Novonesis, the Danish biosolutions group has reported its first full-quarter results and updated outlook. US investors are watching how the new entity integrates operations and targets growth in enzymes and microbial solutions.

Novonesis, formed from the merger of enzyme specialist Novozymes and bioscience group Chr. Hansen, has started to report as a combined company and recently presented its first full quarter of results together with updated 2026 targets, according to a company release published on 04/24/2024Novonesis investor information as of 04/24/2024. The group highlighted cost synergies, integration progress and a focus on high-value biosolutions for food, agriculture and industrial applications, which are closely followed by international investors, including in the United States.

As of: 15.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Novonesis
• Sector/industry: Biosolutions, industrial enzymes and microbial technologies
• Headquarters/country: Denmark
• Core markets: Food and beverages, agriculture, household care, industrial applications
• Key revenue drivers: Enzymes and microbial solutions that improve efficiency and sustainability for customers
• Home exchange/listing venue: Nasdaq Copenhagen (ticker NVO)
• Trading currency: Danish krone (DKK)

Novonesis: core business model

Novonesis positions itself as a global biosolutions leader, combining Novozymes’ enzyme portfolio with Chr. Hansen’s strengths in microbial and fermentation technologies. The company develops biological products that enable customers to replace or reduce chemical inputs and energy use in production, especially in food processing, agriculture and household care applications, as outlined in its corporate presentation released on 01/29/2024Novonesis news overview as of 01/29/2024.

The core business model is based on close collaboration with industrial customers, where Novonesis tailors enzyme and microbial solutions to specific production processes. These solutions typically represent a small share of customers’ total cost but can have a significant impact on yield, quality and environmental footprint, which allows the group to capture attractive margins while offering measurable performance benefits. Recurring demand from long-term contracts and embedded technologies supports a relatively resilient revenue base.

Following the merger, Novonesis organizes its activities into segments that group similar applications and customer industries. The company aims to cross-sell technologies from both legacy businesses and to accelerate innovation by combining research pipelines. Management also emphasizes the importance of sustainability-linked solutions, noting that many products help reduce CO2 emissions or resource consumption for customers, which fits with regulatory and consumer trends globally, including in the US.

Main revenue and product drivers for Novonesis

Food and beverage applications represent one of the largest revenue contributors for Novonesis. Enzymes and cultures are used in baking, dairy, brewing and plant-based foods to optimize texture, taste, shelf life and production efficiency. Demand in this segment is influenced by global population growth, changing dietary preferences and the shift toward healthier and more sustainable products, all of which create opportunities for functional ingredients and fermentation-based innovation.

Agricultural and animal health solutions form another important pillar. Novonesis offers microbial inoculants, silage and feed solutions intended to support crop yields and animal performance with lower reliance on traditional chemical inputs. This segment is driven by the need for more sustainable farming practices and regulatory pressure on fertilizers and antibiotics. Adoption in North and South America is especially relevant because of the large-scale agricultural markets and export-oriented farming sectors.

Household care and industrial biosolutions also contribute significantly to revenue and margins. In laundry detergents, for example, enzymes allow effective washing at lower temperatures and with reduced water and energy consumption. Industrial applications include bioethanol production, textile processing and other sectors where enzymes can replace harsher chemicals. These areas are sensitive to energy prices and environmental regulations, and they offer scalability when customers roll out new formulations across global product lines.

Why Novonesis matters for US investors

For US investors, Novonesis is relevant as a specialized play on industrial biotechnology and sustainable solutions, a theme that cuts across multiple sectors such as food, agriculture and consumer products. Many of the group’s multinational customers operate large US businesses or are headquartered in North America, which ties Novonesis’ growth prospects to trends in the US economy and consumer demand. Exposure to regulatory developments on climate and sustainability in the US can also influence adoption of biosolutions.

Although the primary listing is in Copenhagen and the stock trades in Danish krone, some US investors access the company via international brokerage platforms and global funds that include European life science and industrial innovation names. The merger creating Novonesis has produced a larger entity with broader scale and product reach than the standalone companies, which can matter for index inclusion decisions and for global asset managers that have minimum size thresholds for core positions.

Currency fluctuations between the Danish krone and the US dollar are another aspect for US-based shareholders to consider when assessing reported earnings and potential returns. In addition, the company’s focus on research and development, coupled with exposure to cyclical end markets such as industrial production and certain food categories, can lead to periods of volatility that international investors may weigh against the long-term structural growth narrative for biosolutions.

Conclusion

Novonesis has emerged as a sizable biosolutions group after combining Novozymes and Chr. Hansen, with a diversified portfolio across food, agriculture and industrial applications. The first consolidated reporting periods, including updates in April 2024, underline management’s focus on integration, cost synergies and cross-selling opportunities, as reported on the company’s investor siteNovonesis investor materials as of 04/24/2024. For US investors, the stock offers exposure to industrial biotechnology and sustainability trends but also involves typical risks such as currency effects, execution of merger plans and sensitivity to demand in key end markets. A balanced assessment therefore considers both the structural growth drivers for enzymes and microbial solutions and the integration and market-cycle uncertainties that can influence future financial performance.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.